The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma

BackgroundThe hedgehog pathway inhibitor sonidegib demonstrated meaningful tumor shrinkage in more than 90% of patients with locally advanced basal cell carcinoma (BCC) or metastatic BCC in the BCC Outcomes with LDE225 Treatment study.ObjectiveThis report provides long-term follow-up data collected up to 12 months after the last patient was randomized.MethodsIn this multicenter, randomized, double-blind phase II study, patients were randomized...